13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q3 2024 · Filed November 8, 2024 · Accession 0000950123-24-010733
Total Value
$63.6M
Positions
6
Other Managers
0
Confidential Omitted
No
Holdings (6)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CRISPR Therapeutics AG | CRSP | 498,558 | $23.4M | 36.84% |
| 2 | Contineum Therapeutics, Inc. | CTNM | 918,163 | $17.6M | 27.64% |
| 3 | Repare Therapeutics, Inc. | 760273102 | 2,646,657 | $9.1M | 14.32% |
| 4 | Skye Bioscience, Inc. | SKYE | 2,007,704 | $7.9M | 12.35% |
| 5 | Adverum Biotechnologies, Inc. | 00773U108 | 506,821 | $3.6M | 5.60% |
| 6 | Gritstone Oncology, Inc. | 39868T105 | 3,561,150 | $2.1M | 3.25% |